A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group

Michael S. Isakoff, Robert Goldsby, Doojduen Villaluna, Mark D. Krailo, Pooja Hingorani, Anderson Collier, Carol D. Morris, E. Anders Kolb, John J. Doski, Richard B. Womer, Richard Gorlick, Katherine A. Janeway

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Background: Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving two years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared with other microtubule inhibitors, and may have antitumor activity in osteosarcoma. Methods: A prospective study was designed to assess the disease control success at four months and objective response rates in patients with recurrent or refractory osteosarcoma treated with eribulin. Eligible patients were between 12 and 50 years of age, had measurable tumor, and met standard organ function requirements. Patients were given eribulin 1.4 mg/m2/dose on days 1 and 8 of each 3-week cycle for up to 24 months if there was no progressive disease. Response to therapy was assessed using RECIST 1.1 criteria after cycles 2 and 5 and every fourth cycle thereafter. Results: Nineteen patients enrolled on the AOST1322 study. The median age of enrollment was 16 years (range, 12–25 years). Twelve patients were male and seven female. Eribulin was well tolerated, with neutropenia identified as the most common toxicity. The median progression-free survival was 38 days and no patients reached the four-month time point without progression. No objective responses were seen in any patient. Conclusion: This study rapidly assessed the clinical activity of a novel agent in this patient population. Eribulin was well tolerated, but there were no patients who demonstrated objective response, and all patients had progression prior to four months.

Original languageEnglish (US)
Article numbere27524
JournalPediatric Blood and Cancer
Volume66
Issue number2
DOIs
StatePublished - Feb 2019

Keywords

  • eribulin
  • osteosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

Cite this